JOURNAL 2244


Organic Communications
VOLUME & ISSUE
Available Online: January 02,2022
PAGES
p.1 - 31
DOI ADDRESS
http://doi.org/10.25135/acg.oc.117.2110.2244
(DOI number will be activated after the manuscript has been available in an issue.)
STATISTICS
Viewed 125 times.
AUTHORS
  • Darshini Patel
  • Umang Shah
  • Arya Patel
  • Sandip Patel
  • Mehul Patel
  • Ashish Patel
  • Swayamprakash Patel
  • Nilay Solanki
  • Nilesh Pandey
PDF OF ARTICLE

GRAPHICAL ABSTRACT


ABSTRACT


The SARS-CoV-2 virus, accountable for the COVID-19 pandemic, is now sweeping the globe. As a result, as this disease resists testing and adoption of new treatments, repositioning existing medications may provide a quick and appealing method with established safety, features, and dose used. They are not, however, specific or focused. However, numerous medications have been studied for their efficacy and safety in treatment of COVID-19, with the majority currently undergoing clinical trials. The goal is to rapidly expand novel preventative and therapeutic medications, as well as to apply preventive methods such as early patient identification, isolation, and treatment. Moreover, reducing transmission through physical contact is also important. In the fight against this dangerous disease, finding the proper treatment is crucial. This article summarizes several anti-malarial, anti-parasitic, monoclonal antibodies, immunosuppressant, and immunomodulating agents in clinical trials for COVID-19. The purpose of this article is to evaluate and explore the potential roles of several medications now utilized in COVID-19.

KEYWORDS
  • COVID-19
  • SARS-CoV-2
  • spike protein
  • drug repurposing
  • ACE
  • coronavirus

SUPPORTING INFORMATION


Rebuttal Letter

Manuscript No: OC-2110-2244

Title: Comprehensive Review on Repurposing of Approved Medicine in the Management of COVID-19 Infection

Dear Editor in Chief, 

Sincerest thanks for your response and reviewers’ comments on our manuscript. We sincerely appreciate your and reviewers’ efforts to give a suggestion to improve the quality of article. Herewith I sincerely request and submit the revised copy of manuscript and hope that a revised version of the manuscript will still be considered by reviewers. We have modified the manuscript in response to the extensive and insightful reviewer comments.

We have made changes in the manuscript as mentioned in following table and we hope that this complies with the referee’s remarks.

Reviewer

Comments

Justification

1

 I strongly advise that the English of the whole manuscript should be checked by natives

Corrected across the manuscript and highlighted with yellow/red/blue color

There are so many typo errors such as “extra space (page 4, first sentence; page 11, before section 2.10), abbreviation (page 12, section 2.12), subscript-superscript, hyphen (Figure 1, SARS CoV 2), inconvenience of the upper-lower case letter (Section 2 title, Covid-19) etc.

Errors have been removed

In Figure 1, COVID-19 is not a virus, it is a disease. Revise it

We have corrected on page 2 as per your suggestion.

On page 2, the second paragraph, there is a repetitive sentence “…the virus employs a unique surface glycoprotein termed a “spike”. Revise it

We have omitted the repetitive line “…the virus employs a unique surface glycoprotein termed a “spike on page 2

I think the structures of the molecules (e.g. Chloroquine, Hydroxychloroquine) can be given as a Figure or Scheme with a caption.

Revised and Corrected in the manuscript with figure number which also mentioned in text file too.

 Figure captions should be more annotative. The “role of” what?

Revised in manuscript and highlighted

On page 7 and 10, the type size of Ivermectin and Rapamycin is small compared to the others. Revise it.

All structures of drugs modified in the file and made them uniform across the manuscript

Where is the structure of Cyclosporine (CSA). Please add it.

Structure has been added

The structure of Nitazoxanide is wrong. NH group is missing. Revise it.

Revised in the manuscript

2

Reviewer II Comments

 

Favipiravir is not considered

Favipiravir and Molnupiravir have been added in the manuscript

new emerging drugs could have been listed

the manuscript is not consistent in structure drawings

All structures of drugs modified in the file and made them uniform across the manuscript

 

Thanks, and Regards

Dr. Umang Shah

umangshah.ph@gmail.com

Download File Rebuttal Letter_OC-2110-2244.docx (18.89 KB)